Respiratory Tract Diseases  >>  roflumilast  >>  Phase 4
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
roflumilast / Generic mfg.
NCT01480661 / 2011-004271-36: Evaluation With CT Scan of Possible Changes in Airways After Treatment With Daxas® in Severe Chronic Obstructive Pulmonary Disease Patients

Completed
4
41
Europe
Roflumilast, Daxas®, Placebo of Roflumilast, Functional Respiratory Imaging
FLUIDDA nv
Pulmonary Disease, Chronic Obstructive
04/13
04/13
NCT01849341: Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily

Completed
4
105
Europe
Roflumilast alternated days, schedule change, Roflumilast 500 mcg per day, Standard dosage
Fundación Pública Andaluza Progreso y Salud
Chronic Obstructive Pulmonary Disease (COPD)
12/13
07/14
NCT01329029 / 2010-019685-87: Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

Completed
4
1945
Canada, Europe, RoW
Roflumilast, Placebo
AstraZeneca
Chronic Obstructive Pulmonary Disease
03/14
05/14
NCT01443845 / 2011-003606-24: Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS)

Completed
4
2354
Europe, Canada, US, RoW
Roflumilast, Daliresp, Placebo
AstraZeneca
COPD, COPD Exacerbation, Lung Diseases, Respiratory Disorders, Pulmonary Disease, Chronic Obstructive Lung Diseases, Chronic Obstructive Airway Disease
11/15
01/16
ELASTIC, NCT01630200 / 2011-004152-19: Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)

Completed
4
80
Europe
Roflumilast, Daxas, Placebo
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology, Medical University of Vienna
Chronic Obstructive Pulmonary Disease and Allied Conditions
01/16
01/16
NCT01745848: Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD

Completed
4
26
US
Roflumilast, Daxas, Daliresp
University of Pittsburgh
Chronic Obstructive Pulmonary Disease
06/16
06/16

Download Options